// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE

Claire Harrison - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

AN INNOVATIVE INTERACTIVE CASE-BASED ONLINE EDUCATION TOOL SUBSTANTIALLY INCREASES KNOWLEDGE AND COMPETENCE OF CLINICIANS MANAGING HIGH-RISK AML

Victoria Harvey-Jones - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

PLASMA EXCHANGE, IMMUNOGLOBULIN & PRE-TRANSPLANT IMMUNOSUPPRESSION: AN EFFECTIVE DESENSITISATION STRATEGY FOR DSA ALLOANTIBODIES IN HAPLOIDENTICAL HCT FOR PAEDIATRIC RED CELL DISORDERS

Daniel Dexter - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

Cyclophosphamide

AN AUSTRALIAN/NEW ZEALAND RANDOMIZED TRIAL OF POST-TRANSPLANT CYCLOPHOSPHAMIDE IN MATCHED RELATED PERIPHERAL BLOOD STEM CELL TRANSPLANTS FOR ACUTE LEUKAEMIA OR MYELODYSPLASIA – ALLG BM12

David Curtis - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute Leukemia

Cyclophosphamide

DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY

Andreas Reiter - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Mastocytosis

N/A

CHANGES IN ACUTE HEPATIC PORPHYRIA HEALTH IMPACTS SINCE INITIAL DIAGNOSIS: RESULTS FROM THE PORPHYRIA WORLDWIDE PATIENT EXPERIENCE RESEARCH (POWER) STUDY

Danielle Nance - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Acute hepatic porphyria

ALN-AS1

LONG-TERM TREATMENT WITH ORAL MITAPIVAT IS ASSOCIATED WITH NORMALIZATION OF HEMOGLOBIN LEVELS IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY

Wilma Barcellini - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Pyruvate kinase (PK) deficiency

AG348

REAL-WORLD ASSESSMENT OF TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH LENALIDOMIDE-REFRACTORY RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE OPTUM DATABASE

Binod Dhakal - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Lenalidomide

SYNERGY OF RED BLOOD CELLS AND TRANEXAMIC ACID IN THE INHIBITION OF FIBRINOLYSIS

Alexandra Raska - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Tranexamic acid

THE EVOLVING STATE OF PLAY IN 1000 PATIENTS WITH WALDENSTRÖM'S MACROGLOBULINAEMIA IN THE UNITED KINGDOM (UK): A REAL-WORLD DATA ANALYSIS FROM THE WMUK RORY MORRISON REGISTRY PROJECT

Encarl Uppal - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

COMPUTATIONAL SIMULATIONS SHED LIGHT ON THE 3D CONSEQUENCE OF SUPER-ENHANCER HIJACKING IN B CELL MALIGNANCIES

Lisa Russell - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

PATIENT-REPORTED OUTCOMES IN MYELOPROLIFERATIVE NEOPLASMS IN CLINICAL TRIALS: A SYSTEMATIC REVIEW

Esther Natalie Oliva - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

N/A

HEALTH-RELATED QUALITY OF LIFE IN THE LOCOMMOTION STUDY OF REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Michel Delforge - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

DYNAMIC CHANGES IN THE HISTONE H3 LYSINE 27 TRIMETHYLATION EPIGENETIC LANDSCAPE FOLLOWING RUXOLITINIB ADMINISTRATION

Graeme Greenfield - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Ruxolitinib phosphate

SUSTAINED RESPONSE OFF TREATMENT IN ELTROMBOPAG-TREATED PATIENTS WITH ITP WHO ARE REFRACTORY OR RELAPSED AFTER FIRST-LINE STEROIDS: PRIMARY ANALYSIS OF THE PHASE II TAPER TRIAL

Nichola Cooper - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Eltrombopag

SUCCESSFUL OUTCOME OF A PATIENT WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AZACYTIDINE AND AVAPRITINIB: A CASE REPORT

Chandan Saha - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Mastocytosis

Vidaza

COMPARING THE PSYCHOSOCIAL IMPACTS OF THE COVID-19 PANDEMIC BETWEEN HAEMATOLOGICAL CANCER AND MYELOMA PATIENTS: FINDINGS FROM AN ONLINE SURVEY

Stephen James Quinn - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)

Vikas Gupta - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thrombocytopenia

Ruxolitinib phosphate

REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION STUDY

Hermann Einsele - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

REAL-WORLD CLINICAL OUTCOMES AFTER 3 AND 6 MONTHS OF TREATMENT WITH FEDRATINIB FOLLOWING RUXOLITINIB FAILURE

John Mascarenhas - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

Copyright © 2026. QuantiNova All rights reserved